T1	tradename 114 122	TAXOTERE
T2	tradename 185 204	TAXOTERE. TAXOTERE
T3	activeingredient 206 216	docetaxel)
T4	routeofadministration 240 251	Intravenous
T5	routeofadministration 262 265	IV)
T6	fdaapprovaldate 290 294	1996
T7	adversereaction 305 375	TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS,
T8	adversereaction 380 395	FLUID RETENTION
T9	adversereaction 483 492	mortality
T10	adversereaction 508 532	abnormal liver function,
T11	indication 571 576	NSCLC
T12	tradename 620 628	TAXOTERE
T13	dose 632 641	100 mg/m2
T14	adversereaction 1029 1040	neutropenia
T15	adversereaction 1061 1078	hypersensitivity,
T16	adversereaction 1105 1117	anaphylaxis,
T17	tradename 1244 1252	TAXOTERE
T18	adversereaction 1347 1373	hypersensitivity reactions
T19	tradename 1377 1385	TAXOTERE
T20	inactiveingredient 1414 1428	polysorbate 80
T21	adversereaction 1450 1465	fluid retention
T22	tradename 1741 1741	
T23	chemoclass 1747 1768	microtubule inhibitor
T24	indication 1793 1806	Breast Cancer
T25	co-administereddrug 1902 1913	doxorubicin
T26	co-administereddrug 1918 1934	cyclophosphamide
T27	indication 2002 2037	Non-Small Cell Lung Cancer (NSCLC):
T28	indication 2087 2092	NSCLC
T29	co-administereddrug 2135 2144	cisplatin
T30	indication 2205 2210	NSCLC
T31	indication 2228 2270	Hormone Refractory Prostate Cancer (HRPC):
T32	co-administereddrug 2276 2286	prednisone
T33	indication 2343 2358	prostate cancer
T34	indication 2375 2403	Gastric Adenocarcinoma (GC):
T35	co-administereddrug 2409 2418	cisplatin
T36	co-administereddrug 2423 2435	fluorouracil
T37	indication 2520 2580	Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN):
T38	co-administereddrug 2586 2595	cisplatin
T39	co-administereddrug 2600 2612	fluorouracil
T40	indication 2657 2662	SCCHN
T41	adversereaction 2813 2825	anaphylaxis)
T42	routeofadministration 2838 2856	intravenously (IV)
T43	frequency 2867 2881	every 3 weeks.
T44	tradename 2955 2963	TAXOTERE
T45	indication 2989 3023	BC locally advanced or metastatic:
T46	dose 3024 3032	60 mg/m2
T47	dose 3036 3045	100 mg/m2
T48	indication 3076 3088	BC adjuvant:
T49	dose 3089 3097	75 mg/m2
T50	co-administereddrug 3124 3135	doxorubicin
T51	dose 3136 3144	50 mg/m2
T52	co-administereddrug 3150 3166	cyclophosphamide
T53	dose 3167 3176	500 mg/m2
T54	frequency 3177 3203	every 3 weeks for 6 cycles
T55	indication 3220 3226	NSCLC:
T56	dose 3259 3267	75 mg/m2
T57	indication 3297 3303	NSCLC:
T58	dose 3324 3332	75 mg/m2
T59	co-administereddrug 3345 3354	cisplatin
T60	dose 3355 3363	75 mg/m2
T61	indication 3381 3386	HRPC:
T62	dose 3387 3395	75 mg/m2
T63	dose 3401 3405	5 mg
T64	co-administereddrug 3406 3416	prednisone
T65	frequency 3417 3428	twice a day
T66	dose 3462 3470	75 mg/m2
T67	co-administereddrug 3483 3492	cisplatin
T68	dose 3493 3501	75 mg/m2
T69	co-administereddrug 3536 3548	fluorouracil
T70	dose 3549 3558	750 mg/m2
T71	frequency 3559 3566	per day
T72	routeofadministration 3578 3580	IV
T73	co-administereddrug 3612 3621	cisplatin
T74	indication 3648 3654	SCCHN:
T75	dose 3655 3663	75 mg/m2
T76	dose 3686 3694	75 mg/m2
T77	routeofadministration 3695 3697	IV
T78	co-administereddrug 3720 3732	fluorouracil
T79	dose 3733 3742	750 mg/m2
T80	routeofadministration 3762 3764	IV
T81	co-administereddrug 3796 3805	cisplatin
T82	indication 3846 3852	SCCHN:
T83	dose 3853 3861	75 mg/m2
T84	co-administereddrug 3874 3883	cisplatin
T85	dose 3884 3893	100 mg/m2
T86	routeofadministration 3894 3896	IV
T87	co-administereddrug 3918 3930	fluorouracil
T88	dose 3931 3941	1000 mg/m2
T89	frequency 3942 3949	per day
T90	routeofadministration 3961 3963	IV
T91	routeofadministration 4041 4045	oral
T92	co-administereddrug 4046 4061	corticosteroids
T93	tradename 4195 4204	TAXOTERE:
T94	activeingredient 4357 4366	docetaxel
T95	inactiveingredient 4370 4384	polysorbate 80
T96	adversereaction 4523 4546	Acute myeloid leukemia:
T97	tradename 4572 4581	TAXOTERE,
T98	adversereaction 4637 4651	myelodysplasia
T99	adversereaction 4655 4671	myeloid leukemia
T100	adversereaction 4689 4709	Cutaneous reactions:
T101	adversereaction 4730 4757	erythema of the extremities
T102	adversereaction 4763 4768	edema
T103	adversereaction 4781 4793	desquamation
T104	adversereaction 4805 4825	Severe skin toxicity
T105	adversereaction 4871 4892	Neurologic reactions:
T106	adversereaction 4914 4939	paresthesia, dysesthesia,
T107	adversereaction 4944 4948	pain
T108	adversereaction 4960 4988	Severe neurosensory symptoms
T109	adversereaction 5064 5106	Eye disorders: Cystoid macular edema (CME)
T110	adversereaction 5182 5191	Asthenia:
T111	adversereaction 5199 5207	asthenia
T112	tradename 5329 5337	TAXOTERE
T113	tradename 5668 5676	TAXOTERE
T114	tradename 5808 5816	TAXOTERE
T115	adversereaction 5833 6100	infections, neutropenia, anemia, febrile neutropenia, hypersensitivity, thrombocytopenia, neuropathy, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, mucositis, alopecia, skin reactions, myalgia
T116	company 6153 6176	sanofi-aventis U.S. LLC
T117	activeingredient 6400 6409	docetaxel
T118	adversereaction 7094 7136	TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA,
T119	adversereaction 7157 7184	HYPERSENSITIVITY REACTIONS,
T120	adversereaction 7189 7204	FLUID RETENTION
T121	indication 7295 7308	Breast Cancer
T122	indication 7334 7360	Non-Small Cell Lung Cancer
T123	indication 7395 7410	Prostate Cancer
T124	indication 7430 7452	Gastric Adenocarcinoma
T125	indication 7477 7497	Head and Neck Cancer
T126	indication 7566 7579	Breast Cancer
T127	indication 7607 7633	Non-Small Cell Lung Cancer
T128	indication 7653 7668	Prostate Cancer
T129	indication 7688 7710	Gastric Adenocarcinoma
T130	indication 7740 7760	Head and Neck Cancer
T131	indication 8104 8117	Breast Cancer
T132	indication 8174 8187	Breast Cancer
T133	indication 8213 8239	Non-Small Cell Lung Cancer
T134	indication 8280 8314	Hormone Refractory Prostate Cancer
T135	adversereaction 8319 8331	Toxic Deaths
T136	indication 8337 8359	Gastric Adenocarcinoma
T137	indication 8388 8408	Head and Neck Cancer
T138	adversereaction 8413 8432	Hematologic Effects
T139	adversereaction 8452 8478	Hypersensitivity Reactions
T140	adversereaction 8483 8498	Fluid Retention
T141	adversereaction 8560 8582	Acute Myeloid Leukemia
T142	adversereaction 8587 8605	Cutaneous Reaction
T143	adversereaction 8624 8644	Neurologic Reactions
T144	adversereaction 8677 8690	Eye Disorders
T145	adversereaction 8731 8739	Asthenia
T146	adversereaction 8911 8982	TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS,
T147	adversereaction 8987 9002	FLUID RETENTION
T148	adversereaction 9040 9049	mortality
T149	tradename 9066 9074	TAXOTERE
T150	indication 9195 9224	non-small cell lung carcinoma
T151	tradename 9303 9311	TAXOTERE
T152	dose 9343 9352	100 mg/m2
T153	tradename 9391 9399	TAXOTERE
T154	adversereaction 9737 9856	grade 4 neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity,
T155	adversereaction 9861 9873	toxic death.
T156	adversereaction 9964 9983	febrile neutropenia
T157	tradename 10145 10153	TAXOTERE
T158	tradename 10200 10208	TAXOTERE
T159	adversereaction 10333 10345	neutropenia,
T160	tradename 10581 10589	TAXOTERE
T161	adversereaction 10635 10661	hypersensitivity reactions
T162	adversereaction 10691 10717	rash/erythema, hypotension
T163	adversereaction 10725 10738	bronchospasm,
T164	adversereaction 10760 10772	anaphylaxis,
T165	co-administereddrug 10825 10838	dexamethasone
T166	adversereaction 10854 10880	Hypersensitivity reactions
T167	tradename 10922 10930	TAXOTERE
T168	tradename 11020 11028	TAXOTERE
T169	adversereaction 11088 11114	hypersensitivity reactions
T170	tradename 11118 11126	TAXOTERE
T171	inactiveingredient 11161 11175	polysorbate 80
T172	adversereaction 11212 11227	fluid retention
T173	co-administereddrug 11287 11300	dexamethasone
T174	adversereaction 11402 11419	peripheral edema,
T175	adversereaction 11432 11455	edema, pleural effusion
T176	adversereaction 11483 11490	dyspnea
T177	adversereaction 11500 11518	cardiac tamponade,
T178	adversereaction 11522 11553	pronounced abdominal distention
T179	adversereaction 11562 11570	ascites)
T180	indication 11640 11653	Breast Cancer
T181	tradename 11655 11663	TAXOTERE
T182	indication 11743 11756	breast cancer
T183	tradename 11795 11803	TAXOTERE
T184	co-administereddrug 11824 11835	doxorubicin
T185	co-administereddrug 11840 11856	cyclophosphamide
T186	indication 11937 11951	breast cancer.
T187	indication 11957 11983	Non-Small Cell Lung Cancer
T188	tradename 11985 11993	TAXOTERE
T189	indication 12091 12117	non-small cell lung cancer
T190	tradename 12171 12179	TAXOTERE
T191	co-administereddrug 12200 12209	cisplatin
T192	indication 12303 12329	non-small cell lung cancer
T193	indication 12401 12416	Prostate Cancer
T194	tradename 12418 12426	TAXOTERE
T195	co-administereddrug 12447 12457	prednisone
T196	indication 12548 12575	metastatic prostate cancer.
T197	indication 12581 12603	Gastric Adenocarcinoma
T198	tradename 12605 12613	TAXOTERE
T199	co-administereddrug 12634 12643	cisplatin
T200	co-administereddrug 12648 12660	fluorouracil
T201	indication 12718 12741	gastric adenocarcinoma,
T202	indication 12752 12800	adenocarcinoma of the gastroesophageal junction,
T203	indication 13007 13027	Head and Neck Cancer
T204	tradename 13029 13037	TAXOTERE
T205	co-administereddrug 13058 13067	cisplatin
T206	co-administereddrug 13072 13084	fluorouracil
T207	indication 13160 13213	squamous cell carcinoma of the head and neck (SCCHN).
T208	adversereaction 13422 13434	anaphylaxis)
T209	indication 13441 13454	Breast Cancer
T210	indication 13501 13514	breast cancer
T211	tradename 13576 13584	TAXOTERE
T212	dose 13588 13596	60 mg/m2
T213	dose 13600 13609	100 mg/m2
T214	routeofadministration 13623 13636	intravenously
T215	frequency 13649 13663	every 3 weeks.
T216	indication 13714 13742	node-positive breast cancer,
T217	tradename 13759 13767	TAXOTERE
T218	dose 13776 13784	75 mg/m2
T219	co-administereddrug 13811 13822	doxorubicin
T220	dose 13823 13831	50 mg/m2
T221	co-administereddrug 13836 13852	cyclophosphamide
T222	dose 13853 13862	500 mg/m2
T223	frequency 13863 13891	every 3 weeks for 6 courses.
T224	indication 14016 14042	Non-Small Cell Lung Cancer
T225	tradename 14120 14128	TAXOTERE
T226	dose 14187 14195	75 mg/m2
T227	routeofadministration 14209 14222	intravenously
T228	frequency 14235 14249	every 3 weeks.
T229	dose 14260 14269	100 mg/m2
T230	tradename 14598 14606	TAXOTERE
T231	co-administereddrug 14641 14651	cisplatin.
T232	tradename 14676 14684	TAXOTERE
T233	dose 14688 14696	75 mg/m2
T234	routeofadministration 14710 14723	intravenously
T235	co-administereddrug 14760 14769	cisplatin
T236	dose 14770 14778	75 mg/m2
T237	frequency 14798 14811	every 3 weeks
T238	indication 14856 14871	Prostate Cancer
T239	indication 14887 14933	hormone-refractory metastatic prostate cancer,
T240	tradename 14958 14966	TAXOTERE
T241	dose 14970 14978	75 mg/m2
T242	frequency 14979 14992	every 3 weeks
T243	routeofadministration 15005 15016	intravenous
T244	co-administereddrug 15180 15190	Prednisone
T245	dose 15191 15195	5 mg
T246	routeofadministration 15196 15202	orally
T247	frequency 15203 15214	twice daily
T248	indication 15288 15310	Gastric Adenocarcinoma
T249	indication 15326 15349	gastric adenocarcinoma,
T250	tradename 15374 15382	TAXOTERE
T251	dose 15386 15394	75 mg/m2
T252	routeofadministration 15407 15418	intravenous
T253	co-administereddrug 15441 15450	cisplatin
T254	dose 15451 15460	75 mg/m2,
T255	routeofadministration 15478 15489	intravenous
T256	co-administereddrug 15533 15545	fluorouracil
T257	dose 15546 15555	750 mg/m2
T258	frequency 15556 15563	per day
T259	routeofadministration 15594 15605	intravenous
T260	co-administereddrug 15654 15663	cisplatin
T261	frequency 15697 15715	every three weeks.
T262	co-administereddrug 15757 15768	antiemetics
T263	co-administereddrug 15799 15808	cisplatin
T264	indication 15868 15888	Head and Neck Cancer
T265	co-administereddrug 15931 15943	antiemetics,
T266	co-administereddrug 15990 15999	cisplatin
T267	tradename 16109 16117	TAXOTERE
T268	indication 16329 16335	SCCHN,
T269	tradename 16360 16368	TAXOTERE
T270	dose 16372 16380	75 mg/m2
T271	routeofadministration 16393 16404	intravenous
T272	co-administereddrug 16426 16435	cisplatin
T273	dose 16436 16444	75 mg/m2
T274	routeofadministration 16445 16458	intravenously
T275	co-administereddrug 16496 16508	fluorouracil
T276	routeofadministration 16525 16536	intravenous
T277	dose 16549 16558	750 mg/m2
T278	frequency 16559 16581	per day for five days.
T279	frequency 16611 16638	every 3 weeks for 4 cycles.
T280	indication 16934 16940	SCCHN,
T281	tradename 16965 16973	TAXOTERE
T282	dose 16977 16985	75 mg/m2
T283	routeofadministration 16998 17009	intravenous
T284	co-administereddrug 17041 17050	cisplatin
T285	dose 17051 17060	100 mg/m2
T286	co-administereddrug 17121 17133	fluorouracil
T287	dose 17134 17144	1000 mg/m2
T288	frequency 17144 17148	/day
T289	frequency 17225 17252	every 3 weeks for 3 cycles.
T290	routeofadministration 17427 17431	oral
T291	co-administereddrug 17432 17447	corticosteroids
T292	indication 17463 17479	prostate cancer)
T293	co-administereddrug 17488 17501	dexamethasone
T294	dose 17502 17507	16 mg
T295	frequency 17508 17515	per day
T296	dose 17523 17527	8 mg
T297	frequency 17528 17540	twice daily)
T298	tradename 17576 17584	TAXOTERE
T299	adversereaction 17649 17664	fluid retention
T300	adversereaction 17692 17718	hypersensitivity reactions
T301	indication 17912 17958	hormone-refractory metastatic prostate cancer,
T302	co-administereddrug 17987 17998	prednisone,
T303	routeofadministration 18040 18044	oral
T304	co-administereddrug 18045 18058	dexamethasone
T305	dose 18059 18064	8 mg,
T306	tradename 18108 18116	TAXOTERE
T307	indication 18206 18219	Breast Cancer
T308	dose 18256 18265	100 mg/m2
T309	adversereaction 18292 18312	febrile neutropenia,
T310	adversereaction 18389 18408	cutaneous reactions
T311	tradename 18416 18424	TAXOTERE
T312	dose 18470 18479	100 mg/m2
T313	dose 18483 18492	75 mg/m2.
T314	dose 18592 18600	75 mg/m2
T315	dose 18604 18612	55 mg/m2
T316	dose 18702 18710	60 mg/m2
T317	adversereaction 18831 18851	cutaneous reactions,
T318	adversereaction 18862 18883	peripheral neuropathy
T319	tradename 18891 18899	TAXOTERE
T320	adversereaction 18972 18993	peripheral neuropathy
T321	tradename 19006 19014	TAXOTERE
T322	tradename 19074 19082	TAXOTERE
T323	indication 19112 19125	Breast Cancer
T324	tradename 19126 19134	TAXOTERE
T325	co-administereddrug 19155 19166	doxorubicin
T326	co-administereddrug 19171 19187	cyclophosphamide
T327	adversereaction 19291 19310	febrile neutropenia
T328	tradename 19447 19455	TAXOTERE
T329	dose 19472 19480	60 mg/m.
T330	adversereaction 19518 19528	stomatitis
T331	tradename 19547 19555	TAXOTERE
T332	dose 19574 19582	60 mg/m.
T333	adversereaction 19628 19647	cutaneous reactions
T334	tradename 19702 19710	TAXOTERE
T335	tradename 19747 19755	TAXOTERE
T336	dose 19769 19776	75 mg/m
T337	dose 19780 19788	60 mg/m.
T338	dose 19847 19855	60 mg/m,
T339	indication 19891 19917	Non-Small Cell Lung Cancer
T340	tradename 19935 19943	TAXOTERE
T341	indication 19948 19953	NSCLC
T342	dose 20051 20059	75 mg/m2
T343	adversereaction 20086 20106	febrile neutropenia,
T344	adversereaction 20182 20202	cutaneous reactions,
T345	tradename 20258 20266	TAXOTERE
T346	dose 20361 20370	55 mg/m2.
T347	adversereaction 20408 20429	peripheral neuropathy
T348	tradename 20442 20450	TAXOTERE
T349	tradename 20510 20518	TAXOTERE
T350	tradename 20588 20596	TAXOTERE
T351	dose 20597 20605	75 mg/m2
T352	co-administereddrug 20626 20636	cisplatin,
T353	adversereaction 20761 20781	febrile neutropenia,
T354	tradename 20843 20851	TAXOTERE
T355	dose 20901 20909	65 mg/m2
T356	dose 21114 21122	50 mg/m2
T357	indication 21217 21232	Prostate Cancer
T358	tradename 21258 21266	TAXOTERE
T359	indication 21271 21316	hormone-refractory metastatic prostate cancer
T360	tradename 21317 21325	TAXOTERE
T361	adversereaction 21436 21456	febrile neutropenia,
T362	adversereaction 21532 21551	cutaneous reactions
T363	tradename 21606 21614	TAXOTERE
T364	tradename 21649 21657	TAXOTERE
T365	dose 21671 21678	75 mg/m
T366	dose 21682 21690	60 mg/m.
T367	dose 21749 21757	60 mg/m,
T368	indication 21797 21828	Gastric or Head and Neck Cancer
T369	tradename 21829 21837	TAXOTERE
T370	co-administereddrug 21858 21867	cisplatin
T371	co-administereddrug 21872 21884	fluorouracil
T372	indication 21888 21926	gastric cancer or head and neck cancer
T373	tradename 21949 21957	TAXOTERE
T374	co-administereddrug 21978 21987	cisplatin
T375	co-administereddrug 21992 22004	fluorouracil
T376	co-administereddrug 22018 22029	antiemetics
T377	adversereaction 22196 22216	febrile neutropenia,
T378	adversereaction 22231 22258	infection with neutropenia,
T379	adversereaction 22262 22299	neutropenia lasting more than 7 days.
T380	adversereaction 22317 22359	febrile neutropenia, prolonged neutropenia
T381	adversereaction 22363 22384	neutropenic infection
T382	tradename 22415 22423	TAXOTERE
T383	dose 22452 22460	75 mg/m2
T384	dose 22464 22472	60 mg/m2
T385	adversereaction 22501 22524	complicated neutropenia
T386	tradename 22535 22543	TAXOTERE
T387	dose 22572 22580	60 mg/m2
T388	dose 22584 22592	45 mg/m2
T389	adversereaction 22606 22630	grade 4 thrombocytopenia
T390	tradename 22635 22643	TAXOTERE
T391	dose 22672 22680	75 mg/m2
T392	dose 22684 22693	60 mg/m2.
T393	tradename 22753 22761	TAXOTERE
T394	tradename 23038 23046	TAXOTERE
T395	co-administereddrug 23067 23076	cisplatin
T396	co-administereddrug 23081 23093	fluorouracil
T397	tradename 23199 23207	TAXOTERE
T398	co-administereddrug 23228 23237	Cisplatin
T399	co-administereddrug 23242 23254	Fluorouracil
T400	adversereaction 23284 23300	Diarrhea grade 3
T401	co-administereddrug 23323 23335	fluorouracil
T402	tradename 23378 23386	TAXOTERE
T403	adversereaction 23400 23416	Diarrhea grade 4
T404	tradename 23439 23447	TAXOTERE
T405	co-administereddrug 23452 23464	fluorouracil
T406	adversereaction 23519 23547	Stomatitis/mucositis grade 3
T407	co-administereddrug 23571 23583	fluorouracil
T408	co-administereddrug 23618 23630	fluorouracil
T409	tradename 23685 23693	TAXOTERE
T410	adversereaction 23708 23736	Stomatitis/mucositis grade 4
T411	co-administereddrug 23758 23770	fluorouracil
T412	tradename 23826 23834	TAXOTERE
T413	adversereaction 23849 23867	Liver dysfunction:
T414	tradename 24178 24186	TAXOTERE
T415	tradename 24267 24275	TAXOTERE
T416	co-administereddrug 24323 24332	cisplatin
T417	co-administereddrug 24337 24349	fluorouracil
T418	adversereaction 24357 24371	gastric cancer
T419	co-administereddrug 24398 24407	Cisplatin
T420	adversereaction 24438 24460	Peripheral neuropathy:
T421	co-administereddrug 24796 24805	cisplatin
T422	adversereaction 24862 24874	Ototoxicity:
T423	adversereaction 24933 24948	Nephrotoxicity:
T424	adversereaction 24967 24991	rise in serum creatinine
T425	co-administereddrug 25199 25208	cisplatin
T426	co-administereddrug 25415 25424	Cisplatin
T427	co-administereddrug 25478 25487	cisplatin
T428	co-administereddrug 25593 25602	cisplatin
T429	co-administereddrug 25692 25701	cisplatin
T430	co-administereddrug 25778 25787	cisplatin
T431	co-administereddrug 25860 25869	cisplatin
T432	co-administereddrug 25966 25975	cisplatin
T433	co-administereddrug 26055 26064	cisplatin
T434	co-administereddrug 26148 26157	cisplatin
T435	co-administereddrug 26343 26355	Fluorouracil
T436	adversereaction 26400 26408	diarrhea
T437	adversereaction 26413 26424	stomatitis,
T438	adversereaction 26474 26498	plantar-palmar toxicity,
T439	co-administereddrug 26499 26511	fluorouracil
T440	co-administereddrug 26550 26562	fluorouracil
T441	adversereaction 26647 26655	alopecia
T442	adversereaction 26660 26667	anemia,
T443	co-administereddrug 26855 26867	fluorouracil
T444	activeingredient 27400 27409	docetaxel
T445	tradename 27586 27594	TAXOTERE
T446	tradename 27730 27738	TAXOTERE
T447	tradename 27853 27861	TAXOTERE
T448	tradename 28038 28046	TAXOTERE
T449	tradename 28225 28233	TAXOTERE
T450	tradename 28501 28509	TAXOTERE
T451	tradename 28702 28710	TAXOTERE
T452	tradename 28734 28742	TAXOTERE
T453	tradename 29214 29222	TAXOTERE
T454	tradename 29246 29254	TAXOTERE
T455	tradename 29415 29423	TAXOTERE
T456	tradename 29548 29556	TAXOTERE
T457	tradename 29698 29706	TAXOTERE
T458	tradename 29882 29890	TAXOTERE
T459	activeingredient 29920 29930	docetaxel/
T460	tradename 30200 30208	TAXOTERE
T461	tradename 30304 30312	TAXOTERE
T462	tradename 30426 30434	TAXOTERE
T463	tradename 30581 30589	TAXOTERE
T464	routeofadministration 30603 30614	intravenous
T465	tradename 30699 30707	TAXOTERE
T466	tradename 30867 30875	TAXOTERE
T467	routeofadministration 30921 30934	intravenously
T468	tradename 31041 31049	TAXOTERE
T469	tradename 31145 31153	TAXOTERE
T470	routeofadministration 31300 31311	intravenous
T471	tradename 31711 31719	TAXOTERE
T472	tradename 31745 31753	TAXOTERE
T473	tradename 31763 31771	TAXOTERE
T474	activeingredient 31773 31783	docetaxel)
T475	activeingredient 31824 31833	docetaxel
T476	inactiveingredient 31863 31897	polysorbate 80/dehydrated alcohol.
T477	tradename 31899 31907	TAXOTERE
T478	tradename 31919 31927	TAXOTERE
T479	activeingredient 31929 31939	docetaxel)
T480	activeingredient 31980 31989	docetaxel
T481	inactiveingredient 32016 32050	polysorbate 80/dehydrated alcohol.
T482	tradename 32084 32092	TAXOTERE
T483	activeingredient 32183 32192	docetaxel
T484	inactiveingredient 32227 32242	polysorbate 80.
T485	adversereaction 32272 32284	anaphylaxis,
T486	tradename 32348 32356	TAXOTERE
T487	adversereaction 32469 32481	Toxic Deaths
T488	indication 32483 32496	Breast Cancer
T489	tradename 32497 32505	TAXOTERE
T490	dose 32522 32531	100 mg/m2
T491	adversereaction 32552 32558	deaths
T492	indication 32632 32656	metastatic breast cancer
T493	dose 32935 32943	60 mg/m2
T494	adversereaction 32946 32955	mortality
T495	adversereaction 33123 33129	deaths
T496	adversereaction 33163 33169	Sepsis
T497	adversereaction 33204 33211	deaths.
T498	indication 33213 33239	Non-Small Cell Lung Cancer
T499	tradename 33240 33248	TAXOTERE
T500	dose 33275 33284	100 mg/m2
T501	indication 33333 33359	non-small cell lung cancer
T502	adversereaction 33463 33472	mortality
T503	adversereaction 33559 33565	deaths
T504	dose 33604 33612	75 mg/m2
T505	adversereaction 33693 33702	mortality
T506	dose 33710 33718	75 mg/m2
T507	tradename 34101 34109	TAXOTERE
T508	tradename 34287 34296	TAXOTERE.
T509	tradename 34357 34365	TAXOTERE
T510	tradename 34512 34520	TAXOTERE
T511	adversereaction 34571 34589	severe neutropenia
T512	adversereaction 34634 34654	febrile neutropenia,
T513	adversereaction 34660 34677	grade 4 infection
T514	tradename 34683 34691	TAXOTERE
T515	adversereaction 34738 34749	Neutropenia
T516	dose 34816 34824	60 mg/m2
T517	dose 34828 34837	100 mg/m2
T518	tradename 34841 34849	TAXOTERE
T519	adversereaction 34854 34873	grade 4 neutropenia
T520	dose 34926 34935	100 mg/m2
T521	dose 34962 34971	60 mg/m2.
T522	tradename 35063 35071	TAXOTERE
T523	adversereaction 35150 35169	Febrile neutropenia
T524	dose 35210 35219	100 mg/m2
T525	dose 35260 35269	60 mg/m2.
T526	adversereaction 35270 35326	Hematologic responses, febrile reactions and infections,
T527	adversereaction 35340 35352	septic death
T528	indication 35454 35467	breast cancer
T529	adversereaction 35552 35577	gastrointestinal bleeding
T530	adversereaction 35614 35631	thrombocytopenia.
T531	indication 35636 35650	gastric cancer
T532	activeingredient 35673 35682	docetaxel
T533	co-administereddrug 35703 35712	cisplatin
T534	co-administereddrug 35717 35729	fluorouracil
T535	adversereaction 35737 35756	febrile neutropenia
T536	adversereaction 35764 35785	neutropenic infection
T537	adversereaction 35953 35972	febrile neutropenia
T538	adversereaction 35977 35998	neutropenic infection
T539	adversereaction 36066 36092	Hypersensitivity Reactions
T540	adversereaction 36134 36161	hypersensitivity reactions,
T541	adversereaction 36219 36245	hypersensitivity reactions
T542	adversereaction 36275 36301	rash/erythema, hypotension
T543	adversereaction 36309 36322	bronchospasm,
T544	adversereaction 36344 36356	anaphylaxis,
T545	co-administereddrug 36416 36432	corticosteroids.
T546	adversereaction 36440 36466	hypersensitivity reactions
T547	tradename 36508 36516	TAXOTERE
T548	tradename 36643 36652	TAXOTERE.
T549	adversereaction 36654 36680	Hypersensitivity reactions
T550	tradename 36738 36746	TAXOTERE
T551	adversereaction 36784 36792	flushing
T552	adversereaction 36796 36820	localized skin reactions
T553	routeofadministration 36913 36917	oral
T554	co-administereddrug 36918 36932	corticosteroid
T555	tradename 36976 36984	TAXOTERE
T556	adversereaction 37157 37172	Fluid Retention
T557	adversereaction 37181 37196	fluid retention
T558	tradename 37225 37233	TAXOTERE
T559	routeofadministration 37280 37284	oral
T560	co-administereddrug 37285 37300	corticosteroids
T561	tradename 37315 37323	TAXOTERE
T562	adversereaction 37379 37394	fluid retention
T563	adversereaction 37597 37613	peripheral edema
T564	indication 37726 37739	breast cancer
T565	co-administereddrug 37773 37789	corticosteroids,
T566	adversereaction 37799 37814	fluid retention
T567	adversereaction 37844 37859	fluid retention
T568	adversereaction 37927 37942	fluid retention
T569	adversereaction 38027 38043	fluid retention:
T570	adversereaction 38080 38096	fluid retention;
T571	adversereaction 38134 38150	fluid retention.
T572	adversereaction 38214 38229	fluid retention
T573	dose 38234 38245	1021 mg/m2.
T574	adversereaction 38246 38261	Fluid retention
T575	tradename 38363 38371	TAXOTERE
T576	adversereaction 38431 38447	peripheral edema
T577	adversereaction 38534 38556	Acute Myeloid Leukemia
T578	adversereaction 38576 38604	acute myeloid leukemia (AML)
T579	adversereaction 38608 38622	myelodysplasia
T580	indication 38732 38746	breast cancer.
T581	indication 38764 38777	breast cancer
T582	tradename 38840 38849	TAXOTERE,
T583	adversereaction 39050 39064	myelodysplasia
T584	adversereaction 39068 39084	myeloid leukemia
T585	adversereaction 39124 39163	Cutaneous Reactions Localized erythema
T586	adversereaction 39188 39193	edema
T587	adversereaction 39206 39218	desquamation
T588	indication 39417 39441	metastatic breast cancer
T589	indication 39461 39474	breast cancer
T590	co-administereddrug 39508 39524	corticosteroids,
T591	tradename 39606 39614	TAXOTERE
T592	adversereaction 39642 39692	Neurologic Reactions Severe neurosensory symptoms
T593	adversereaction 39699 39730	paresthesia, dysesthesia, pain)
T594	indication 39765 39789	metastatic breast cancer
T595	adversereaction 40163 40176	neurotoxicity
T596	adversereaction 40390 40417	peripheral motor neuropathy
T597	adversereaction 40512 40539	Cystoid macular edema (CME)
T598	tradename 40583 40592	TAXOTERE.
T599	adversereaction 40696 40699	CME
T600	tradename 40714 40722	TAXOTERE
T601	adversereaction 40861 40869	Asthenia
T602	adversereaction 40878 40886	asthenia
T603	indication 40927 40951	metastatic breast cancer
T604	activeingredient 41280 41289	docetaxel
T605	tradename 41351 41359	TAXOTERE
T606	tradename 41565 41573	TAXOTERE
T607	tradename 41679 41687	TAXOTERE
T608	dose 41701 41710	100 mg/m2
T609	inactiveingredient 41732 41740	ethanol.
T610	inactiveingredient 41809 41816	ethanol
T611	activeingredient 41847 41856	docetaxel
T612	tradename 41930 41938	TAXOTERE
T613	activeingredient 41999 42008	Docetaxel
T614	tradename 42361 42370	TAXOTERE.
T615	tradename 42374 42382	TAXOTERE
T616	tradename 42637 42645	TAXOTERE
T617	tradename 42904 42912	TAXOTERE
T618	adversereaction 42927 42939	Toxic Deaths
T619	adversereaction 43000 43014	Hepatotoxicity
T620	adversereaction 43076 43087	Neutropenia
T621	adversereaction 43149 43165	Hypersensitivity
T622	adversereaction 43227 43242	Fluid Retention
T623	tradename 43341 43349	TAXOTERE
T624	adversereaction 43378 43625	neutropenia, anemia, febrile neutropenia, hypersensitivity, thrombocytopenia, neuropathy, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, mucositis, alopecia, skin reactions,
T625	adversereaction 43630 43638	myalgia.
T626	indication 44296 44309	Breast Cancer
T627	tradename 44327 44335	TAXOTERE
T628	indication 44340 44384	locally advanced or metastatic breast cancer
T629	tradename 44421 44429	TAXOTERE
T630	dose 44430 44440	100 mg/m2:
T631	tradename 44549 44557	TAXOTERE
T632	dose 44574 44583	100 mg/m2
T633	frequency 44605 44619	every 3 weeks:
T634	indication 44733 44778	locally advanced or metastatic breast cancer,
T635	tradename 45091 45100	TAXOTERE.
T636	tradename 45233 45241	TAXOTERE
T637	indication 45263 45276	breast cancer
T638	tradename 45393 45401	TAXOTERE
T639	dose 45405 45414	100 mg/m2
T640	indication 45479 45492	Breast Cancer
T641	adversereaction 45561 45572	Neutropenia
T642	indication 45970 45983	Breast Cancer
T643	adversereaction 46054 46064	Leukopenia
T644	adversereaction 46123 46139	Thrombocytopenia
T645	adversereaction 46173 46179	Anemia
T646	adversereaction 46228 46248	Febrile Neutropenia*
T647	adversereaction 46260 46289	Septic Death Non-Septic Death
T648	adversereaction 46306 46316	Infections
T649	adversereaction 46348 46353	Fever
T650	adversereaction 46405 46431	Hypersensitivity Reactions
T651	adversereaction 46554 46569	Fluid Retention
T652	indication 47065 47078	Breast Cancer
T653	adversereaction 47156 47168	Nail Changes
T654	adversereaction 47216 47240	Nausea Vomiting Diarrhea
T655	adversereaction 47286 47296	Stomatitis
T656	adversereaction 47328 47336	Alopecia
T657	adversereaction 47346 47354	Asthenia
T658	adversereaction 47388 47395	Myalgia
T659	adversereaction 47426 47436	Arthralgia
T660	adversereaction 47443 47466	Infusion Site Reactions
T661	adversereaction 47777 47797	Febrile Neutropenia:
T662	adversereaction 47815 47820	fever
T663	routeofadministration 47835 47846	intravenous
T664	adversereaction 47905 47934	Reversible marrow suppression
T665	tradename 47975 47983	TAXOTERE
T666	adversereaction 48088 48106	severe neutropenia
T667	adversereaction 48292 48311	Febrile neutropenia
T668	routeofadministration 48356 48367	intravenous
T669	indication 48608 48633	metastatic breast cancer,
T670	indication 48652 48665	breast cancer
T671	co-administereddrug 48699 48715	corticosteroids.
T672	indication 48817 48842	metastatic breast cancer,
T673	indication 48861 48874	breast cancer
T674	co-administereddrug 48908 48924	corticosteroids.
T675	adversereaction 48926 48942	Thrombocytopenia
T676	adversereaction 48983 49016	fatal gastrointestinal hemorrhage
T677	adversereaction 49037 49097	Hypersensitivity Reactions Severe hypersensitivity reactions
T678	adversereaction 49194 49208	flushing, rash
T679	adversereaction 49225 49283	pruritus, chest tightness, back pain, dyspnea, drug fever,
T680	adversereaction 49287 49294	chills,
T681	adversereaction 49398 49430	Fluid Retention. Fluid retention
T682	tradename 49457 49465	TAXOTERE
T683	adversereaction 49553 49593	Cutaneous Reactions Severe skin toxicity
T684	adversereaction 49718 49722	rash
T685	adversereaction 49850 49859	pruritus,
T686	tradename 49929 49937	TAXOTERE
T687	adversereaction 50016 50030	nail disorders
T688	adversereaction 50053 50080	hypo- or hyperpigmentation,
T689	adversereaction 50101 50112	onycholysis
T690	adversereaction 50157 50205	pain. Neurologic Reactions Neurologic reactions
T691	adversereaction 50308 50325	Nausea, vomiting,
T692	adversereaction 50330 50338	diarrhea
T693	indication 50465 50489	metastatic breast cancer
T694	indication 50560 50573	breast cancer
T695	adversereaction 50632 50642	stomatitis
T696	indication 50716 50741	metastatic breast cancer,
T697	indication 50764 50777	breast cancer
T698	co-administereddrug 50811 50827	corticosteroids.
T699	adversereaction 50854 50865	Hypotension
T700	adversereaction 50976 51038	heart failure, sinus tachycardia, atrial flutter, dysrhythmia,
T701	adversereaction 51277 51293	pulmonary edema,
T702	adversereaction 51298 51310	hypertension
T703	indication 51350 51374	metastatic breast cancer
T704	tradename 51394 51402	TAXOTERE
T705	dose 51403 51412	100 mg/m2
T706	adversereaction 51617 51664	Infusion Site Reactions Infusion site reactions
T707	adversereaction 51702 51766	hyperpigmentation, inflammation, redness or dryness of the skin,
T708	adversereaction 51778 51792	extravasation,
T709	adversereaction 51796 51817	swelling of the vein.
T710	tradename 52105 52114	TAXOTERE,
T711	tradename 52712 52720	TAXOTERE
T712	dose 52724 52733	100 mg/m2
T713	indication 52778 52802	metastatic breast cancer
T714	tradename 53048 53056	TAXOTERE
T715	dose 53060 53068	60 mg/m2
T716	indication 53155 53168	Breast Cancer
T717	tradename 53226 53234	TAXOTERE
T718	dose 53235 53244	100 mg/m2
T719	dose 53294 53302	60 mg/m2
T720	tradename 53355 53363	TAXOTERE
T721	dose 53364 53373	100 mg/m2
T722	tradename 53375 53383	TAXOTERE
T723	dose 53384 53392	60 mg/m2
T724	adversereaction 53464 53475	Neutropenia
T725	adversereaction 53552 53568	Thrombocytopenia
T726	adversereaction 53646 53652	Anemia
T727	tradename 53975 53983	TAXOTERE
T728	dose 53984 53993	100 mg/m2
T729	tradename 53995 54003	TAXOTERE
T730	dose 54004 54012	60 mg/m2
T731	adversereaction 54084 54094	Infection*
T732	adversereaction 54135 54155	Febrile Neutropenia*
T733	adversereaction 54198 54210	Septic Death
T734	adversereaction 54217 54233	Non-Septic Death
T735	routeofadministration 54601 54612	intravenous
T736	adversereaction 54786 54806	Febrile Neutropenia:
T737	dose 54811 54821	100 mg/m2,
T738	routeofadministration 54857 54868	intravenous
T739	dose 54909 54918	60 mg/m2,
T740	indication 55001 55014	Breast Cancer
T741	tradename 55073 55081	TAXOTERE
T742	dose 55082 55091	100 mg/m2
T743	dose 55142 55150	60 mg/m2
T744	tradename 55204 55212	TAXOTERE
T745	dose 55213 55222	100 mg/m2
T746	tradename 55224 55232	TAXOTERE
T747	dose 55233 55241	60 mg/m2
T748	adversereaction 55313 55335	Acute Hypersensitivity
T749	adversereaction 55403 55419	Fluid Retention*
T750	tradename 55827 55835	TAXOTERE
T751	dose 55836 55845	100 mg/m2
T752	tradename 55847 55855	TAXOTERE
T753	dose 55856 55864	60 mg/m2
T754	adversereaction 55966 55973	Myalgia
T755	adversereaction 56024 56032	Asthenia
T756	adversereaction 56065 56073	Diarrhea
T757	adversereaction 56103 56113	Stomatitis
T758	adversereaction 56460 56475	Fluid Retention
T759	adversereaction 56499 56504	edema
T760	dose 56688 56696	60 mg/m2
T761	tradename 56781 56789	TAXOTERE
T762	dose 56790 56798	60 mg/m2
T763	dose 56801 56809	75 mg/m2
T764	dose 56814 56823	100 mg/m2
T765	indication 56827 56850	advanced breast cancer,
T766	tradename 56932 56940	TAXOTERE
T767	dose 56941 56949	60 mg/m2
T768	dose 56991 56999	75 mg/m2
T769	dose 57004 57013	100 mg/m2
T770	dose 57117 57125	60 mg/m2
T771	dose 57169 57185	75 and 100 mg/m2
T772	adversereaction 57200 57206	Deaths
T773	dose 57282 57290	60 mg/m2
T774	dose 57341 57349	75 mg/m2
T775	dose 57354 57363	100 mg/m2
T776	activeingredient 57442 57451	docetaxel
T777	adversereaction 57459 57474	fluid retention
T778	dose 57497 57516	60 mg/m2, 75 mg/m2,
T779	dose 57521 57530	100 mg/m2
T780	adversereaction 57546 57562	thrombocytopenia
T781	adversereaction 57595 57606	neutropenia
T782	adversereaction 57641 57660	febrile neutropenia
T783	adversereaction 57693 57730	treatment-related grade 3/4 infection
T784	adversereaction 57765 57771	anemia
T785	tradename 58054 58062	TAXOTERE
T786	indication 58092 58105	breast cancer
T787	tradename 58220 58228	TAXOTERE
T788	dose 58229 58236	75 mg/m
T789	frequency 58237 58250	every 3 weeks
T790	co-administereddrug 58271 58282	doxorubicin
T791	co-administereddrug 58287 58303	cyclophosphamide
T792	tradename 58443 58451	TAXOTERE
T793	co-administereddrug 58472 58483	Doxorubicin
T794	co-administereddrug 58489 58505	Cyclophosphamide
T795	tradename 58516 58524	TAXOTERE
T796	dose 58525 58534	75 mg/m2+
T797	co-administereddrug 58535 58546	Doxorubicin
T798	dose 58547 58556	50 mg/m2+
T799	co-administereddrug 58557 58573	Cyclophosphamide
T800	dose 58574 58584	500 mg/m2
T801	dose 58614 58624	500 mg/m2+
T802	dose 58637 58646	50 mg/m2+
T803	dose 58664 58674	500 mg/m2
T804	adversereaction 58736 58742	Anemia
T805	adversereaction 58753 58764	Neutropenia
T806	adversereaction 58777 58782	Fever
T807	adversereaction 58817 58826	Infection
T808	adversereaction 58837 58853	Thrombocytopenia
T809	adversereaction 58864 58883	Febrile neutropenia
T810	adversereaction 58897 58918	Neutropenic infection
T811	adversereaction 58932 58958	Hypersensitivity reactions
T812	adversereaction 58968 58978	Lymphedema
T813	adversereaction 58987 59032	Fluid Retention* Peripheral edema Weight gain
T814	adversereaction 59066 59084	Neuropathy sensory
T815	adversereaction 59095 59109	Neuro-cortical
T816	adversereaction 59118 59134	Neuropathy motor
T817	adversereaction 59143 59159	Neuro-cerebellar
T818	adversereaction 59168 59175	Syncope
T819	adversereaction 59184 59192	Alopecia
T820	adversereaction 59207 59220	Skin toxicity
T821	adversereaction 59231 59245	Nail disorders
T822	adversereaction 59256 59262	Nausea
T823	adversereaction 59274 59284	Stomatitis
T824	adversereaction 59295 59303	Vomiting
T825	adversereaction 59314 59322	Diarrhea
T826	adversereaction 59333 59345	Constipation
T827	adversereaction 59356 59372	Taste perversion
T828	tradename 59563 59571	TAXOTERE
T829	dose 59572 59581	75 mg/m2+
T830	co-administereddrug 59582 59593	Doxorubicin
T831	dose 59594 59603	50 mg/m2+
T832	co-administereddrug 59604 59620	Cyclophosphamide
T833	dose 59621 59631	500 mg/m2
T834	dose 59661 59671	500 mg/m2+
T835	dose 59684 59693	50 mg/m2+
T836	dose 59711 59721	500 mg/m2
T837	adversereaction 59783 59791	Anorexia
T838	adversereaction 59802 59816	Abdominal Pain
T839	adversereaction 59826 59836	Amenorrhea
T840	adversereaction 59851 59856	Cough
T841	adversereaction 59867 59887	Cardiac dysrhythmias
T842	adversereaction 59896 59910	Vasodilatation
T843	adversereaction 59921 59932	Hypotension
T844	adversereaction 59941 59950	Phlebitis
T845	adversereaction 59959 59967	Asthenia
T846	adversereaction 59979 59986	Myalgia
T847	adversereaction 59997 60007	Arthralgia
T848	adversereaction 60017 60037	Lacrimation disorder
T849	adversereaction 60047 60061	Conjunctivitis
T850	adversereaction 60318 60338	hematologic toxicity
T851	adversereaction 60542 60547	fever
T852	adversereaction 60580 60587	allergy
T853	adversereaction 60785 60790	Fever
T854	adversereaction 60929 60934	fever
T855	adversereaction 61035 61044	Infection
T856	adversereaction 61140 61149	infection
T857	adversereaction 61431 61476	colitis/enteritis/large intestine perforation
T858	adversereaction 61923 61936	dysrhythmias,
T859	adversereaction 61965 61977	hypotension,
T860	adversereaction 62009 62012	CHF
T861	adversereaction 62113 62141	Acute Myeloid Leukemia (AML)
T862	adversereaction 62160 62182	acute myeloid leukemia
T863	adversereaction 62186 62200	myelodysplasia
T864	indication 62322 62336	breast cancer.
T865	adversereaction 62338 62341	AML
T866	adversereaction 62438 62441	AML
T867	indication 62467 62480	breast cancer
T868	adversereaction 62549 62552	AML
T869	adversereaction 62657 62660	AML
T870	tradename 62818 62826	TAXOTERE
T871	indication 62845 62881	locally advanced or metastatic NSCLC
T872	tradename 62934 62942	TAXOTERE
T873	dose 62943 62952	75 mg/m2:
T874	indication 63089 63118	non-small cell lung carcinoma
T875	tradename 63527 63535	TAXOTERE
T876	indication 63555 63581	Non-Small Cell Lung Cancer
T877	tradename 63655 63663	TAXOTERE
T878	dose 63664 63672	75 mg/m2
T879	adversereaction 63747 63758	Neutropenia
T880	adversereaction 63795 63805	Leukopenia
T881	adversereaction 63840 63856	Thrombocytopenia
T882	adversereaction 63887 63893	Anemia
T883	tradename 64253 64261	TAXOTERE
T884	dose 64262 64270	75 mg/m2
T885	adversereaction 64345 64365	Febrile Neutropenia*
T886	adversereaction 64382 64391	Infection
T887	adversereaction 64444 64453	Mortality
T888	adversereaction 64469 64495	Hypersensitivity Reactions
T889	adversereaction 64526 64541	Fluid Retention
T890	adversereaction 64728 64734	Nausea
T891	adversereaction 64749 64757	Vomiting
T892	adversereaction 64772 64780	Diarrhea
T893	adversereaction 64849 64857	Alopecia
T894	adversereaction 64867 64875	Asthenia
T895	adversereaction 64912 64922	Stomatitis
T896	tradename 65150 65158	TAXOTERE
T897	dose 65159 65167	75 mg/m2
T898	adversereaction 65313 65326	Nail Disorder
T899	adversereaction 65355 65362	Myalgia
T900	adversereaction 65390 65400	Arthralgia
T901	adversereaction 65428 65444	Taste Perversion
T902	adversereaction 65661 65681	Febrile Neutropenia:
T903	routeofadministration 65718 65729	intravenous
T904	tradename 65875 65883	TAXOTERE
T905	indication 65906 65947	advanced unresectable or metastatic NSCLC
T906	indication 66104 66130	non-small cell lung cancer
T907	indication 66614 66640	Non-Small Cell Lung Cancer
T908	tradename 66660 66668	TAXOTERE
T909	co-administereddrug 66691 66700	Cisplatin
T910	tradename 66721 66729	TAXOTERE
T911	dose 66730 66738	75 mg/m2
T912	co-administereddrug 66741 66750	Cisplatin
T913	dose 66751 66759	75 mg/m2
T914	dose 66782 66790	25 mg/m2
T915	dose 66803 66812	100 mg/m2
T916	adversereaction 66823 66834	Neutropenia
T917	adversereaction 66864 66883	Febrile Neutropenia
T918	adversereaction 66888 66904	Thrombocytopenia
T919	adversereaction 66932 66938	Anemia
T920	adversereaction 66967 66976	Infection
T921	adversereaction 67004 67009	Fever
T922	adversereaction 67066 67092	Hypersensitivity Reaction*
T923	adversereaction 67124 67140	Fluid Retention*
T924	adversereaction 67191 67207	Pleural effusion
T925	adversereaction 67262 67278	Peripheral edema
T926	adversereaction 67333 67344	Weight gain
T927	tradename 67726 67734	TAXOTERE
T928	dose 67735 67743	75 mg/m2
T929	co-administereddrug 67746 67755	Cisplatin
T930	dose 67756 67764	75 mg/m2
T931	dose 67787 67795	25 mg/m2
T932	dose 67808 67817	100 mg/m2
T933	adversereaction 67902 67908	Nausea
T934	adversereaction 67938 67946	Vomiting
T935	adversereaction 67975 67983	Diarrhea
T936	adversereaction 68011 68020	Anorexia*
T937	adversereaction 68077 68087	Stomatitis
T938	adversereaction 68115 68123	Alopecia
T939	adversereaction 68153 68162	Asthenia*
T940	adversereaction 68221 68235	Nail Disorder*
T941	adversereaction 68279 68287	Myalgia*
T942	adversereaction 68398 68404	Deaths
T943	activeingredient 68482 68492	docetaxel+
T944	co-administereddrug 68492 68501	cisplatin
T945	adversereaction 68563 68569	Deaths
T946	activeingredient 68671 68681	docetaxel+
T947	co-administereddrug 68681 68690	cisplatin
T948	tradename 69004 69013	TAXOTERE+
T949	co-administereddrug 69013 69024	carboplatin
T950	tradename 69088 69097	TAXOTERE,
T951	adversereaction 69165 69261	thrombocytopenia, diarrhea, fluid retention, hypersensitivity reactions, skin toxicity, alopecia
T952	adversereaction 69266 69278	nail changes
T953	tradename 69286 69295	TAXOTERE+
T954	co-administereddrug 69295 69306	carboplatin
T955	indication 69459 69474	Prostate Cancer
T956	tradename 69500 69508	TAXOTERE
T957	indication 69526 69541	prostate cancer
T958	tradename 69628 69636	TAXOTERE
T959	dose 69637 69644	75 mg/m
T960	frequency 69645 69658	every 3 weeks
T961	co-administereddrug 69679 69689	prednisone
T962	dose 69690 69694	5 mg
T963	routeofadministration 69695 69701	orally
T964	frequency 69702 69713	twice daily
T965	indication 69844 69859	Prostate Cancer
T966	tradename 69873 69881	TAXOTERE
T967	co-administereddrug 69903 69913	Prednisone
T968	tradename 69923 69931	TAXOTERE
T969	dose 69932 69940	75 mg/m2
T970	frequency 69942 69955	every 3 weeks
T971	co-administereddrug 69958 69968	prednisone
T972	dose 69969 69973	5 mg
T973	frequency 69974 69986	twice daily
T974	dose 70010 70018	12 mg/m2
T975	frequency 70019 70032	every 3 weeks
T976	dose 70047 70051	5 mg
T977	frequency 70052 70063	twice daily
T978	adversereaction 70120 70126	Anemia
T979	adversereaction 70137 70148	Neutropenia
T980	adversereaction 70161 70177	Thrombocytopenia
T981	adversereaction 70186 70205	Febrile neutropenia
T982	adversereaction 70218 70227	Infection
T983	adversereaction 70238 70247	Epistaxis
T984	adversereaction 70256 70274	Allergic Reactions
T985	adversereaction 70283 70330	Fluid Retention* Weight Gain* Peripheral Edema*
T986	adversereaction 70415 70432	Rash/Desquamation
T987	adversereaction 70464 70476	Nail Changes
T988	adversereaction 70486 70492	Nausea
T989	adversereaction 70503 70511	Diarrhea
T990	adversereaction 70522 70544	Stomatitis/Pharyngitis
T991	tradename 70753 70761	TAXOTERE
T992	dose 70762 70770	75 mg/m2
T993	frequency 70771 70784	every 3 weeks
T994	co-administereddrug 70788 70798	prednisone
T995	dose 70799 70803	5 mg
T996	frequency 70804 70815	twice daily
T997	dose 70839 70847	12 mg/m2
T998	frequency 70848 70861	every 3 weeks
T999	dose 70876 70880	5 mg
T1000	frequency 70881 70892	twice daily
T1001	adversereaction 70949 70966	Taste Disturbance
T1002	adversereaction 70976 70984	Vomiting
T1003	adversereaction 70995 71003	Anorexia
T1004	adversereaction 71014 71019	Cough
T1005	adversereaction 71029 71036	Dyspnea
T1006	adversereaction 71046 71079	Cardiac left ventricular function
T1007	adversereaction 71091 71098	Fatigue
T1008	adversereaction 71109 71116	Myalgia
T1009	adversereaction 71127 71134	Tearing
T1010	adversereaction 71144 71154	Arthralgia
T1011	tradename 71226 71234	TAXOTERE
T1012	indication 71238 71260	gastric adenocarcinoma
T1013	indication 71347 71369	gastric adenocarcinoma
T1014	tradename 71451 71459	TAXOTERE
T1015	dose 71460 71468	75 mg/m2
T1016	co-administereddrug 71489 71498	cisplatin
T1017	co-administereddrug 71503 71515	fluorouracil
T1018	indication 71650 71664	Gastric Cancer
T1019	tradename 71673 71681	TAXOTERE
T1020	dose 71682 71690	75 mg/m2
T1021	co-administereddrug 71693 71702	cisplatin
T1022	dose 71703 71711	75 mg/m2
T1023	co-administereddrug 71715 71727	fluorouracil
T1024	dose 71728 71737	750 mg/m2
T1025	dose 71755 71764	100 mg/m2
T1026	dose 71780 71790	1000 mg/m2
T1027	adversereaction 71856 71862	Anemia
T1028	adversereaction 71875 71886	Neutropenia
T1029	adversereaction 71899 71904	Fever
T1030	adversereaction 71945 71961	Thrombocytopenia
T1031	adversereaction 71973 71982	Infection
T1032	adversereaction 71995 72014	Febrile neutropenia
T1033	tradename 72244 72252	TAXOTERE
T1034	dose 72253 72261	75 mg/m2
T1035	co-administereddrug 72264 72273	cisplatin
T1036	dose 72274 72282	75 mg/m2
T1037	co-administereddrug 72286 72298	fluorouracil
T1038	dose 72299 72308	750 mg/m2
T1039	dose 72326 72335	100 mg/m2
T1040	dose 72351 72361	1000 mg/m2
T1041	adversereaction 72427 72448	Neutropenic infection
T1042	adversereaction 72463 72481	Allergic reactions
T1043	adversereaction 72491 72507	Fluid retention*
T1044	adversereaction 72517 72523	Edema*
T1045	adversereaction 72596 72605	Dizziness
T1046	adversereaction 72615 72623	Alopecia
T1047	adversereaction 72634 72643	Rash/itch
T1048	adversereaction 72653 72665	Nail changes
T1049	adversereaction 72700 72706	Nausea
T1050	adversereaction 72719 72727	Vomiting
T1051	adversereaction 72740 72748	Anorexia
T1052	adversereaction 72761 72771	Stomatitis
T1053	adversereaction 72784 72792	Diarrhea
T1054	adversereaction 72804 72816	Constipation
T1055	adversereaction 72827 72861	Esophagitis/dysphagia/ odynophagia
T1056	adversereaction 72874 72904	Gastrointestinal pain/cramping
T1057	adversereaction 72916 72936	Cardiac dysrhythmias
T1058	adversereaction 72945 72964	Myocardial ischemia
T1059	adversereaction 72973 72980	Tearing
T1060	adversereaction 72989 73004	Altered hearing
T1061	indication 73191 73211	Head and Neck Cancer
T1062	tradename 73237 73245	TAXOTERE
T1063	indication 73249 73269	head and neck cancer
T1064	tradename 73371 73379	TAXOTERE
T1065	dose 73380 73388	75 mg/m2
T1066	co-administereddrug 73409 73418	cisplatin
T1067	co-administereddrug 73423 73435	fluorouracil
T1068	indication 74097 74102	SCCHN
T1069	tradename 74142 74150	TAXOTERE
T1070	co-administereddrug 74171 74180	cisplatin
T1071	co-administereddrug 74185 74197	fluorouracil
T1072	tradename 74295 74303	TAXOTERE
T1073	tradename 74341 74349	TAXOTERE
T1074	adversereaction 74502 74513	Neutropenia
T1075	adversereaction 74538 74544	Anemia
T1076	adversereaction 74568 74584	Thrombocytopenia
T1077	adversereaction 74607 74616	Infection
T1078	adversereaction 74637 74657	Febrile neutropenia*
T1079	adversereaction 74683 74704	Neutropenic infection
T1080	adversereaction 74731 74742	Cancer pain
T1081	adversereaction 74764 74772	Lethargy
T1082	adversereaction 74794 74799	Fever
T1083	adversereaction 74849 74856	Myalgia
T1084	adversereaction 74874 74885	Weight loss
T1085	adversereaction 74906 74913	Allergy
T1086	adversereaction 74930 74946	Fluid retention*
T1087	adversereaction 74948 74953	Edema
T1088	adversereaction 74959 74970	Weight gain
T1089	adversereaction 75038 75047	Dizziness
T1090	adversereaction 75099 75114	Altered hearing
T1091	adversereaction 75162 75170	Alopecia
T1092	adversereaction 75192 75201	Rash/itch
T1093	adversereaction 75221 75229	Dry skin
T1094	adversereaction 75246 75258	Desquamation
T1095	adversereaction 75275 75281	Nausea
T1096	adversereaction 75304 75314	Stomatitis
T1097	adversereaction 75338 75346	Vomiting
T1098	adversereaction 75368 75376	Diarrhea
T1099	adversereaction 75397 75409	Constipation
T1100	adversereaction 75430 75438	Anorexia
T1101	adversereaction 75461 75495	Esophagitis/dysphagia/ Odynophagia
T1102	tradename 75778 75786	TAXOTERE
T1103	tradename 75824 75832	TAXOTERE
T1104	adversereaction 75985 76014	Taste, sense of smell altered
T1105	adversereaction 76035 76065	Gastrointestinal pain/cramping
T1106	adversereaction 76085 76094	Heartburn
T1107	adversereaction 76113 76138	Gastrointestinal bleeding
T1108	adversereaction 76156 76175	Cardiac dysrhythmia
T1109	adversereaction 76218 76237	Ischemia myocardial
T1110	adversereaction 76254 76261	Tearing
T1111	adversereaction 76278 76292	Conjunctivitis
T1112	adversereaction 76424 76444	Febrile neutropenia:
T1113	adversereaction 76461 76466	fever
T1114	adversereaction 76484 76503	grade 4 neutropenia
T1115	routeofadministration 76514 76525	intravenous
T1116	adversereaction 76933 76987	diffuse pain, chest pain, radiation recall phenomenon.
T1117	adversereaction 77005 77149	atrial fibrillation, deep vein thrombosis, ECG abnormalities, thrombophlebitis, pulmonary embolism, syncope, tachycardia, myocardial infarction.
T1118	adversereaction 77181 77210	cutaneous lupus erythematosus
T1119	adversereaction 77229 77246	bullous eruptions
T1120	adversereaction 77255 77329	erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis,
T1121	adversereaction 77334 77358	Scleroderma-like changes
T1122	adversereaction 77379 77401	peripheral lymphedema.
T1123	adversereaction 77498 77520	hand and foot syndrome
T1124	adversereaction 77559 77770	abdominal pain, anorexia, constipation, duodenal ulcer, esophagitis, gastrointestinal hemorrhage, gastrointestinal perforation, ischemic colitis, colitis, intestinal obstruction, ileus, neutropenic enterocolitis
T1125	adversereaction 78010 78075	bleeding episodes. Disseminated intravascular coagulation (DIC),
T1126	adversereaction 78102 78108	sepsis
T1127	adversereaction 78112 78131	multiorgan failure,
T1128	adversereaction 78161 78183	acute myeloid leukemia
T1129	adversereaction 78188 78211	myelodysplasic syndrome
T1130	tradename 78251 78259	TAXOTERE
T1131	adversereaction 78370 78388	anaphylactic shock
T1132	adversereaction 78525 78535	hepatitis,
T1133	adversereaction 78642 78652	confusion,
T1134	adversereaction 78667 78675	seizures
T1135	adversereaction 78679 78710	transient loss of consciousness
T1136	adversereaction 78801 78828	conjunctivitis, lacrimation
T1137	adversereaction 78876 78893	Excessive tearing
T1138	adversereaction 78983 79012	transient visual disturbances
T1139	adversereaction 79014 79050	flashes, flashing lights, scotomata)
T1140	adversereaction 79116 79142	hypersensitivity reactions
T1141	adversereaction 79232 79259	cystoid macular edema (CME)
T1142	tradename 79304 79313	TAXOTERE.
T1143	adversereaction 79338 79368	ototoxicity, hearing disorders
T1144	adversereaction 79376 79388	hearing loss
T1145	adversereaction 79486 79629	acute pulmonary edema, acute respiratory distress syndrome/pneumonitis, interstitial lung disease, interstitial pneumonia, respiratory failure,
T1146	adversereaction 79634 79652	pulmonary fibrosis
T1147	adversereaction 79735 79756	radiation pneumonitis
T1148	adversereaction 79832 79851	renal insufficiency
T1149	adversereaction 79856 79869	renal failure
T1150	adversereaction 80016 80028	hyponatremia
T1151	activeingredient 80072 80081	Docetaxel
T1152	activeingredient 80156 80165	docetaxel
T1153	activeingredient 80339 80348	docetaxel
T1154	activeingredient 80519 80529	docetaxel.
T1155	tradename 80549 80557	TAXOTERE
T1156	activeingredient 80613 80622	docetaxel
T1157	tradename 80683 80692	TAXOTERE,
T1158	tradename 80729 80737	TAXOTERE
T1159	tradename 81230 81238	TAXOTERE
T1160	tradename 81302 81310	TAXOTERE
T1161	tradename 81565 81584	TAXOTERE. TAXOTERE
T1162	dose 81687 81713	&#x2265;0.3 and 0.03 mg/kg
T1163	frequency 81713 81718	/day,
T1164	tradename 81879 81887	TAXOTERE
T1165	activeingredient 82137 82146	docetaxel
T1166	tradename 82304 82313	TAXOTERE,
T1167	tradename 82504 82512	TAXOTERE
T1168	tradename 82641 82649	TAXOTERE
T1169	tradename 82761 82769	TAXOTERE
T1170	tradename 82878 82886	TAXOTERE
T1171	co-administereddrug 83012 83021	cisplatin
T1172	co-administereddrug 83026 83046	5-fluoruracil (TCF).
T1173	tradename 83048 83056	TAXOTERE
T1174	tradename 83069 83077	TAXOTERE
T1175	dose 83396 83405	125 mg/m2
T1176	routeofadministration 83418 83429	intravenous
T1177	frequency 83439 83453	every 21 days.
T1178	adversereaction 83494 83506	neutropenia.
T1179	tradename 83533 83541	TAXOTERE
T1180	tradename 84000 84008	TAXOTERE
T1181	tradename 84024 84032	TAXOTERE
T1182	co-administereddrug 84065 84074	cisplatin
T1183	co-administereddrug 84079 84099	5-fluorouracil (TCF)
T1184	tradename 84355 84363	TAXOTERE
T1185	dose 84365 84373	75 mg/m)
T1186	co-administereddrug 84394 84403	cisplatin
T1187	dose 84405 84413	75 mg/m)
T1188	co-administereddrug 84418 84432	5-fluorouracil
T1189	dose 84434 84443	750 mg/m)
T1190	dose 84467 84475	80 mg/m)
T1191	dose 84496 84505	1000 mg/m
T1192	frequency 84505 84510	/day)
T1193	activeingredient 84782 84791	docetaxel
T1194	activeingredient 84854 84863	docetaxel
T1195	dose 84882 84890	55 mg/m2
T1196	dose 84894 84903	235 mg/m2
T1197	routeofadministration 84916 84927	intravenous
T1198	frequency 84938 84951	every 3 weeks
T1199	activeingredient 85005 85014	docetaxel
T1200	clearance 85030 85045	17.310.9 L/h/m2
T1201	activeingredient 85050 85059	Docetaxel
T1202	co-administereddrug 85097 85106	cisplatin
T1203	co-administereddrug 85111 85132	5-fluorouracil (TCF),
T1204	dose 85151 85159	75 mg/m2
T1205	routeofadministration 85172 85183	intravenous
T1206	activeingredient 85286 85295	Docetaxel
T1207	clearance 85310 85325	17.98.75 L/h/m2
T1208	auc 85355 85371	4.202.57 g.h/mL.
T1209	activeingredient 85429 85438	docetaxel
T1210	indication 85942 85968	Non-Small Cell Lung Cancer
T1211	indication 86026 86031	NSCLC
T1212	tradename 86068 86077	TAXOTERE+
T1213	co-administereddrug 86077 86086	cisplatin
T1214	tradename 86226 86235	TAXOTERE+
T1215	co-administereddrug 86235 86244	cisplatin
T1216	tradename 86511 86520	TAXOTERE+
T1217	co-administereddrug 86520 86530	cisplatin,
T1218	adversereaction 86531 86539	diarrhea
T1219	adversereaction 86547 86563	peripheral edema
T1220	adversereaction 86574 86584	stomatitis
T1221	tradename 86737 86746	TAXOTERE+
T1222	co-administereddrug 86746 86755	cisplatin
T1223	adversereaction 86823 86831	diarrhea
T1224	adversereaction 86839 86849	infections
T1225	adversereaction 86857 86873	peripheral edema
T1226	adversereaction 86884 86894	stomatitis
T1227	tradename 87023 87031	TAXOTERE
T1228	co-administereddrug 87050 87061	carboplatin
T1229	indication 87103 87142	advanced non-small cell lung carcinoma,
T1230	tradename 87269 87278	TAXOTERE+
T1231	co-administereddrug 87278 87288	cisplatin,
T1232	adversereaction 87315 87334	diarrhea, infection
T1233	adversereaction 87339 87355	peripheral edema
T1234	indication 87415 87430	Prostate Cancer
T1235	tradename 87464 87472	TAXOTERE
T1236	frequency 87473 87490	every three weeks
T1237	co-administereddrug 87496 87506	prednisone
T1238	indication 87514 87529	prostate cancer
T1239	tradename 87658 87666	TAXOTERE
T1240	frequency 87667 87685	every three weeks,
T1241	adversereaction 87843 87849	anemia
T1242	adversereaction 87865 87874	infection
T1243	adversereaction 87890 87902	nail changes
T1244	adversereaction 87918 87926	anorexia
T1245	adversereaction 87942 87953	weight loss
T1246	indication 87982 87995	Breast Cancer
T1247	indication 88012 88025	breast cancer
T1248	tradename 88042 88050	TAXOTERE
T1249	co-administereddrug 88071 88082	doxorubicin
T1250	co-administereddrug 88087 88103	cyclophosphamide
T1251	indication 88368 88382	Gastric Cancer
T1252	tradename 88419 88427	TAXOTERE
T1253	co-administereddrug 88448 88457	cisplatin
T1254	co-administereddrug 88462 88474	fluorouracil
T1255	indication 88482 88496	gastric cancer
T1256	adversereaction 88946 89037	lethargy, stomatitis, diarrhea, dizziness, edema, febrile neutropenia/neutropenic infection
T1257	indication 89354 89374	Head and Neck Cancer
T1258	tradename 89448 89456	TAXOTERE
T1259	co-administereddrug 89477 89486	cisplatin
T1260	co-administereddrug 89491 89503	fluorouracil
T1261	indication 89514 89519	SCCHN
T1262	tradename 89664 89672	TAXOTERE
T1263	co-administereddrug 89693 89702	cisplatin
T1264	co-administereddrug 89707 89719	fluorouracil
T1265	indication 89737 89742	SCCHN
T1266	tradename 90098 90107	TAXOTERE.
T1267	tradename 90228 90236	TAXOTERE
T1268	tradename 90344 90352	TAXOTERE
T1269	tradename 90525 90533	TAXOTERE
T1270	adversereaction 90715 90765	bone marrow suppression, peripheral neurotoxicity,
T1271	adversereaction 90770 90780	mucositis.
T1272	dose 90989 90998	150 mg/m2
T1273	dose 91022 91031	200 mg/m2
T1274	adversereaction 91079 91134	severe neutropenia, mild asthenia, cutaneous reactions,
T1275	adversereaction 91139 91156	mild paresthesia,
T1276	routeofadministration 91239 91250	intravenous
T1277	dose 91275 91284	154 mg/kg
T1278	dose 91320 91329	100 mg/m2
T1279	dose 91467 91475	48 mg/kg
T1280	dose 91511 91520	100 mg/m2
T1281	dose 91590 91598	20 mg/kg
T1282	dose 91632 91641	100 mg/m2
T1283	activeingredient 91751 91760	Docetaxel
T1284	activeingredient 91960 91969	docetaxel
T1285	activeingredient 92268 92277	Docetaxel
T1286	activeingredient 92317 92326	Docetaxel
T1287	molecularweight 92441 92447	861.9.
T1288	tradename 92518 92526	TAXOTERE
T1289	tradename 92550 92558	TAXOTERE
T1290	activeingredient 92560 92570	docetaxel)
T1291	activeingredient 92714 92723	docetaxel
T1292	inactiveingredient 92750 92764	polysorbate 80
T1293	inactiveingredient 92782 92800	dehydrated alcohol
T1294	tradename 92812 92820	TAXOTERE
T1295	activeingredient 92894 92903	docetaxel
T1296	tradename 92919 92927	TAXOTERE
T1297	activeingredient 93093 93102	Docetaxel
T1298	activeingredient 93253 93262	Docetaxel
T1299	activeingredient 93569 93580	Docetaxel's
T1300	activeingredient 93819 93828	docetaxel
T1301	dose 93892 93900	20 mg/m2
T1302	dose 93904 93913	115 mg/m2
T1303	dose 94006 94014	70 mg/m2
T1304	dose 94018 94027	115 mg/m2
T1305	activeingredient 94065 94076	Docetaxel's
T1306	clearance 94278 94287	21 L/h/m2
T1307	activeingredient 94595 94604	docetaxel
T1308	volumeofdistribution 94683 94689	113 L.
T1309	activeingredient 94719 94728	docetaxel
T1310	activeingredient 94969 94979	docetaxel.
T1311	activeingredient 95042 95051	docetaxel
T1312	activeingredient 95297 95306	docetaxel
T1313	activeingredient 95347 95356	Docetaxel
T1314	tradename 95903 95911	TAXOTERE
T1315	dose 95947 95957	100 mg/m2.
T1316	activeingredient 96093 96102	docetaxel
T1317	activeingredient 96276 96286	docetaxel.
T1318	tradename 96939 96948	TAXOTERE.
T1319	dose 97175 97183	10 mg/m2
T1320	dose 97187 97195	90 mg/m2
T1321	dose 97258 97268	100 mg/m2,
T1322	activeingredient 97328 97337	docetaxel
T1323	activeingredient 97618 97627	docetaxel
T1324	activeingredient 97710 97719	docetaxel
T1325	dose 97721 97729	100 mg/m
T1326	routeofadministration 97730 97742	intravenous)
T1327	activeingredient 97752 97761	docetaxel
T1328	dose 97763 97770	10 mg/m
T1329	routeofadministration 97771 97783	intravenous)
T1330	dose 97818 97824	200 mg
T1331	routeofadministration 97825 97831	orally
T1332	frequency 97832 97854	once daily for 3 days)
T1333	activeingredient 97979 97988	docetaxel
T1334	activeingredient 98054 98063	docetaxel
T1335	activeingredient 98232 98241	Docetaxel
T1336	activeingredient 98351 98360	docetaxel
T1337	activeingredient 98466 98476	docetaxel.
T1338	activeingredient 98546 98555	docetaxel
T1339	activeingredient 98676 98686	docetaxel,
T1340	activeingredient 98971 98980	docetaxel
T1341	activeingredient 99087 99096	docetaxel
T1342	indication 99200 99213	breast cancer
T1343	activeingredient 99276 99285	docetaxel
T1344	dose 99287 99295	75 mg/m)
T1345	dose 99310 99318	50 mg/m)
T1346	dose 99342 99351	500 mg/m)
T1347	activeingredient 99410 99419	docetaxel
T1348	activeingredient 99675 99684	docetaxel
T1349	activeingredient 99781 99790	docetaxel
T1350	activeingredient 99920 99929	docetaxel
T1351	activeingredient 99956 99965	Docetaxel
T1352	dose 100108 100126	0.39 to 1.56 mg/kg
T1353	activeingredient 100197 100206	Docetaxel
T1354	activeingredient 100465 100474	Docetaxel
T1355	routeofadministration 100538 100549	intravenous
T1356	dose 100565 100574	0.3 mg/kg
T1357	routeofadministration 100860 100871	intravenous
T1358	dose 100881 100888	5 mg/kg
T1359	dose 100901 100912	0.375 mg/kg
T1360	indication 101151 101164	Breast Cancer
T1361	tradename 101193 101201	TAXOTERE
T1362	indication 101225 101269	locally advanced or metastatic breast cancer
T1363	tradename 101545 101553	TAXOTERE
T1364	dose 101555 101564	100 mg/m2
T1365	frequency 101565 101579	every 3 weeks)
T1366	dose 101613 101621	12 mg/m2
T1367	frequency 101622 101636	every 6 weeks)
T1368	dose 101654 101661	6 mg/m2
T1369	frequency 101662 101676	every 3 weeks)
T1370	tradename 101724 101732	TAXOTERE
T1371	tradename 101858 101866	TAXOTERE
T1372	tradename 102168 102176	TAXOTERE
T1373	indication 102197 102210	Breast Cancer
T1374	activeingredient 102327 102336	Docetaxel
T1375	activeingredient 102470 102480	Docetaxel:
T1376	activeingredient 102622 102632	Docetaxel:
T1377	activeingredient 102824 102834	docetaxel.
T1378	tradename 103156 103164	TAXOTERE
T1379	dose 103166 103176	100 mg/m2)
T1380	dose 103193 103202	75 mg/m2)
T1381	frequency 103203 103217	every 3 weeks.
T1382	tradename 103268 103276	TAXOTERE
T1383	tradename 103663 103671	TAXOTERE
T1384	indication 103692 103705	Breast Cancer
T1385	activeingredient 103819 103828	Docetaxel
T1386	activeingredient 103950 103960	Docetaxel:
T1387	activeingredient 104101 104111	Docetaxel:
T1388	activeingredient 104300 104310	docetaxel.
T1389	indication 104417 104430	breast cancer
T1390	tradename 104536 104544	TAXOTERE
T1391	dose 104557 104565	60 mg/m2
T1392	dose 104575 104583	75 mg/m2
T1393	dose 104595 104604	100 mg/m2
T1394	tradename 104789 104797	TAXOTERE
T1395	dose 104859 104867	75 mg/m2
T1396	dose 104886 104895	100 mg/m2
T1397	dose 104936 104944	60 mg/m2
T1398	dose 104949 104958	100 mg/m2
T1399	tradename 105027 105035	TAXOTERE
T1400	dose 105049 105058	100 mg/m2
T1401	indication 105136 105160	metastatic breast cancer
T1402	indication 105257 105271	breast cancer,
T1403	tradename 105697 105705	TAXOTERE
T1404	dose 105773 105781	60 mg/m2
T1405	indication 105840 105885	locally advanced or metastatic breast cancer.
T1406	dose 106071 106080	100 mg/m2
T1407	indication 106111 106124	Breast Cancer
T1408	tradename 106216 106224	TAXOTERE
T1409	indication 106292 106305	breast cancer
T1410	tradename 106482 106490	TAXOTERE
T1411	dose 106491 106499	75 mg/m2
T1412	co-administereddrug 106526 106537	doxorubicin
T1413	dose 106538 106546	50 mg/m2
T1414	co-administereddrug 106551 106567	cyclophosphamide
T1415	dose 106568 106577	500 mg/m2
T1416	dose 106604 106612	50 mg/m2
T1417	dose 106638 106647	500 mg/m2
T1418	dose 106670 106679	500 mg/m2
T1419	frequency 106723 106750	every 3 weeks for 6 cycles.
T1420	tradename 106752 106760	TAXOTERE
T1421	routeofadministration 106830 106841	intravenous
T1422	co-administereddrug 106981 106990	tamoxifen
T1423	dose 106991 106996	20 mg
T1424	frequency 106997 107021	daily for up to 5 years.
T1425	activeingredient 107322 107342	docetaxel-containing
T1426	indication 108610 108623	Breast Cancer
T1427	indication 109367 109401	Non-Small Cell Lung Cancer (NSCLC)
T1428	tradename 109430 109438	TAXOTERE
T1429	indication 109520 109546	non-small cell lung cancer
T1430	tradename 109667 109675	TAXOTERE
T1431	tradename 109791 109799	TAXOTERE
T1432	dose 109808 109816	75 mg/m2
T1433	tradename 109940 109948	TAXOTERE
T1434	dose 109962 109972	100 mg/m2,
T1435	adversereaction 110015 110048	hematologic toxicity, infections,
T1436	adversereaction 110071 110080	mortality
T1437	indication 110277 110304	non-small cell lung cancer,
T1438	tradename 110428 110436	TAXOTERE
T1439	tradename 110548 110556	TAXOTERE
T1440	dose 110557 110566	100 mg/m2
T1441	adversereaction 110602 110614	toxic deaths
T1442	tradename 110655 110663	TAXOTERE
T1443	dose 110664 110673	75 mg/m2.
T1444	tradename 110746 110754	TAXOTERE
T1445	dose 110755 110763	75 mg/m2
T1446	indication 110878 110905	non-small cell lung cancer,
T1447	tradename 111014 111022	TAXOTERE
T1448	dose 111023 111031	75 mg/m2
T1449	tradename 111034 111042	TAXOTERE
T1450	dose 111043 111052	100 mg/m2
T1451	dose 111120 111128	30 mg/m2
T1452	frequency 111156 111169	every 3 weeks
T1453	dose 111184 111190	2 g/m2
T1454	frequency 111209 111223	every 3 weeks.
T1455	tradename 111388 111396	TAXOTERE
T1456	dose 111397 111405	75 mg/m2
T1457	tradename 111554 111562	TAXOTERE
T1458	indication 111583 111609	Non-Small Cell Lung Cancer
T1459	activeingredient 111727 111736	Docetaxel
T1460	dose 111737 111745	75 mg/m2
T1461	activeingredient 111781 111790	Docetaxel
T1462	dose 111791 111799	75 mg/m2
T1463	activeingredient 112040 112050	Docetaxel:
T1464	activeingredient 112690 112699	docetaxel
T1465	tradename 112929 112937	TAXOTERE
T1466	dose 112938 112946	75 mg/m2
T1467	tradename 112990 112998	TAXOTERE
T1468	dose 112999 113007	75 mg/m2
T1469	tradename 113184 113192	TAXOTERE
T1470	dose 113193 113201	75 mg/m2
T1471	tradename 113263 113271	TAXOTERE
T1472	dose 113285 113293	75 mg/m2
T1473	tradename 113441 113449	TAXOTERE
T1474	indication 113473 113478	NSCLC
T1475	indication 113571 113576	NSCLC
T1476	tradename 113655 113663	TAXOTERE
T1477	dose 113664 113672	75 mg/m2
T1478	co-administereddrug 113718 113727	cisplatin
T1479	dose 113728 113736	75 mg/m2
T1480	frequency 113759 113773	every 3 weeks;
T1481	dose 113786 113794	25 mg/m2
T1482	dose 113869 113878	100 mg/m2
T1483	frequency 113920 113934	every 4 weeks;
T1484	tradename 113955 113963	TAXOTERE
T1485	co-administereddrug 113968 113980	carboplatin.
T1486	tradename 114049 114058	TAXOTERE+
T1487	co-administereddrug 114058 114067	cisplatin
T1488	tradename 114319 114327	TAXOTERE
T1489	co-administereddrug 114331 114340	cisplatin
T1490	tradename 114773 114782	TAXOTERE+
T1491	co-administereddrug 114782 114791	cisplatin
T1492	tradename 114880 114888	TAXOTERE
T1493	indication 114936 114941	NSCLC
T1494	tradename 114955 114964	Taxotere+
T1495	co-administereddrug 114964 114973	Cisplatin
T1496	tradename 115365 115374	TAXOTERE+
T1497	co-administereddrug 115374 115383	cisplatin
T1498	tradename 115426 115435	TAXOTERE+
T1499	co-administereddrug 115435 115444	cisplatin
T1500	tradename 115518 115527	TAXOTERE+
T1501	co-administereddrug 115527 115536	cisplatin
T1502	tradename 115715 115724	TAXOTERE+
T1503	co-administereddrug 115724 115736	carboplatin,
T1504	tradename 115795 115803	TAXOTERE
T1505	tradename 115869 115878	TAXOTERE+
T1506	co-administereddrug 115878 115889	carboplatin
T1507	tradename 115956 115965	TAXOTERE+
T1508	co-administereddrug 115965 115976	carboplatin
T1509	tradename 116242 116251	TAXOTERE+
T1510	co-administereddrug 116251 116260	cisplatin
T1511	tradename 116403 116411	TAXOTERE
T1512	tradename 116476 116485	TAXOTERE+
T1513	co-administereddrug 116485 116494	Cisplatin
T1514	indication 116794 116828	Hormone Refractory Prostate Cancer
T1515	tradename 116857 116865	TAXOTERE
T1516	co-administereddrug 116886 116896	prednisone
T1517	indication 116914 116982	androgen independent (hormone refractory) metastatic prostate cancer
T1518	tradename 117184 117192	TAXOTERE
T1519	dose 117193 117201	75 mg/m2
T1520	frequency 117202 117215	every 3 weeks
T1521	tradename 117240 117248	TAXOTERE
T1522	dose 117249 117257	30 mg/m2
T1523	frequency 117271 117277	weekly
T1524	dose 117354 117362	12 mg/m2
T1525	frequency 117363 117376	every 3 weeks
T1526	dose 117456 117460	5 mg
T1527	frequency 117461 117473	twice daily,
T1528	tradename 117495 117503	TAXOTERE
T1529	frequency 117504 117520	every three week
T1530	tradename 117631 117639	TAXOTERE
T1531	tradename 117766 117774	TAXOTERE
T1532	frequency 117775 117787	every 3 week
T1533	tradename 118033 118041	TAXOTERE
T1534	indication 118076 118144	Androgen Independent (Hormone Refractory) Metastatic Prostate Cancer
T1535	tradename 118173 118182	TAXOTERE+
T1536	co-administereddrug 118183 118193	Prednisone
T1537	frequency 118194 118207	every 3 weeks
T1538	frequency 118234 118247	every 3 weeks
T1539	indication 118695 118717	Gastric Adenocarcinoma
T1540	tradename 118816 118824	TAXOTERE
T1541	indication 118869 118892	gastric adenocarcinoma,
T1542	indication 118903 118951	adenocarcinoma of the gastroesophageal junction,
T1543	tradename 119080 119088	TAXOTERE
T1544	dose 119094 119102	75 mg/m2
T1545	co-administereddrug 119133 119142	cisplatin
T1546	dose 119148 119156	75 mg/m2
T1547	co-administereddrug 119171 119183	fluorouracil
T1548	dose 119189 119198	750 mg/m2
T1549	frequency 119199 119218	per day for 5 days)
T1550	dose 119233 119242	100 mg/m2
T1551	dose 119271 119281	1000 mg/m2
T1552	frequency 119282 119301	per day for 5 days)
T1553	tradename 120606 120614	TAXOTERE
T1554	indication 120649 120671	gastric adenocarcinoma
T1555	tradename 121123 121131	TAXOTERE
T1556	indication 121239 121253	Gastric Cancer
T1557	indication 121540 121554	Gastric Cancer
T1558	indication 121738 121758	Head and Neck Cancer
T1559	tradename 121844 121852	TAXOTERE
T1560	indication 121897 121949	squamous cell carcinoma of the head and neck (SCCHN)
T1561	indication 122083 122089	SCCHN,
T1562	tradename 122187 122195	TAXOTERE
T1563	tradename 122209 122217	TAXOTERE
T1564	dose 122222 122230	75 mg/m2
T1565	co-administereddrug 122243 122252	cisplatin
T1566	dose 122257 122265	75 mg/m2
T1567	co-administereddrug 122288 122300	fluorouracil
T1568	dose 122305 122314	750 mg/m2
T1569	frequency 122386 122417	every three weeks for 4 cycles.
T1570	dose 122588 122597	100 mg/m2
T1571	dose 122637 122648	1000 mg/m2/
T1572	frequency 122714 122745	every three weeks for 4 cycles.
T1573	dose 123147 123160	1.8 Gy-2.0 Gy
T1574	frequency 123161 123188	once a day, 5 days per week
T1575	dose 123209 123221	66 to 70 Gy)
T1576	frequency 123272 123284	twice a day,
T1577	dose 123372 123384	70 to 74 Gy,
T1578	tradename 124145 124153	TAXOTERE
T1579	indication 124226 124231	SCCHN
T1580	tradename 124269 124278	TAXOTERE+
T1581	co-administereddrug 124279 124303	Cisplatin+ Fluorouracil
T1582	tradename 124916 124925	TAXOTERE+
T1583	co-administereddrug 124925 124947	Cisplatin+Fluorouracil
T1584	tradename 125703 125711	TAXOTERE
T1585	indication 125830 125835	SCCHN
T1586	indication 125958 125964	SCCHN,
T1587	tradename 126068 126076	TAXOTERE
T1588	tradename 126090 126098	TAXOTERE
T1589	dose 126103 126110	75 mg/m
T1590	routeofadministration 126114 126125	intravenous
T1591	dose 126170 126178	100 mg/m
T1592	routeofadministration 126221 126232	intravenous
T1593	routeofadministration 126270 126281	intravenous
T1594	dose 126311 126320	1000 mg/m
T1595	frequency 126320 126324	/day
T1596	frequency 126372 126399	every 3 weeks for 3 cycles.
T1597	dose 126455 126463	100 mg/m
T1598	routeofadministration 126493 126504	intravenous
T1599	routeofadministration 126550 126561	intravenous
T1600	dose 126591 126600	1000 mg/m
T1601	frequency 126600 126604	/day
T1602	frequency 126651 126678	every 3 weeks for 3 cycles.
T1603	routeofadministration 126960 126971	intravenous
T1604	dose 127091 127095	2 Gy
T1605	frequency 127096 127132	per day, 5 days per week for 7 weeks
T1606	dose 127153 127162	70-72 Gy)
T1607	tradename 127390 127409	TAXOTERE-containing
T1608	tradename 127764 127772	TAXOTERE
T1609	tradename 127880 127889	TAXOTERE+
T1610	co-administereddrug 127890 127913	Cisplatin+ Fluorouracil
T1611	tradename 128125 128134	TAXOTERE+
T1612	co-administereddrug 128134 128156	cisplatin+fluorouracil
T1613	tradename 129575 129583	TAXOTERE
T1614	tradename 129609 129617	TAXOTERE
T1615	tradename 129724 129732	TAXOTERE
T1616	tradename 129762 129770	TAXOTERE
T1617	activeingredient 129772 129782	docetaxel)
T1618	activeingredient 129823 129832	docetaxel
T1619	inactiveingredient 129863 129897	polysorbate 80/dehydrated alcohol.
T1620	tradename 129946 129954	TAXOTERE
T1621	tradename 129986 129994	TAXOTERE
T1622	activeingredient 129996 130006	docetaxel)
T1623	activeingredient 130047 130056	docetaxel
T1624	inactiveingredient 130084 130118	polysorbate 80/dehydrated alcohol.
T1625	tradename 130597 130605	TAXOTERE
T1626	tradename 130781 130789	TAXOTERE
T1627	tradename 130961 130969	TAXOTERE
T1628	routeofadministration 131025 131029	oral
T1629	adversereaction 131280 131306	hypersensitivity reaction.
T1630	adversereaction 131353 131368	fluid retention
T1631	adversereaction 131377 131393	peripheral edema
T1632	adversereaction 131421 131432	weight gain
T1633	adversereaction 131437 131445	dyspnea.
T1634	adversereaction 131812 131820	myalgia,
T1635	tradename 131934 131942	TAXOTERE
T1636	tradename 132108 132116	TAXOTERE
T1637	adversereaction 132273 132367	nausea, vomiting, diarrhea, constipation, fatigue, excessive tearing, infusion site reactions,
T1638	adversereaction 132372 132381	hair loss
T1639	activeingredient 132402 132411	docetaxel
T1640	tradename 132450 132458	TAXOTERE
T1641	activeingredient 132473 132483	docetaxel)
T1642	routeofadministration 132507 132518	Intravenous
T1643	tradename 132604 132612	TAXOTERE
T1644	tradename 132861 132880	TAXOTERE? TAXOTERE
T1645	adversereaction 132923 132929	death.
T1646	adversereaction 132948 132953	death
T1647	tradename 132976 132984	TAXOTERE
T1648	tradename 133065 133073	TAXOTERE
T1649	indication 133089 133115	non-small cell lung cancer
T1650	tradename 133194 133202	TAXOTERE
T1651	tradename 133296 133305	TAXOTERE.
T1652	tradename 133448 133456	TAXOTERE
T1653	tradename 133707 133716	TAXOTERE.
T1654	adversereaction 133760 133766	fever.
T1655	adversereaction 133781 133799	allergic reactions
T1656	tradename 133830 133839	TAXOTERE.
T1657	adversereaction 133849 133867	allergic reactions
T1658	adversereaction 134403 134419	fluid retention)
T1659	tradename 134442 134451	TAXOTERE.
T1660	co-administereddrug 134560 134575	corticosteroid,
T1661	tradename 134588 134596	TAXOTERE
T1662	co-administereddrug 134627 134641	corticosteroid
T1663	tradename 134715 134723	TAXOTERE
T1664	co-administereddrug 134760 134774	corticosteroid
T1665	tradename 134833 134852	TAXOTERE? TAXOTERE
T1666	indication 134938 134951	breast cancer
T1667	indication 134963 134989	non-small cell lung cancer
T1668	indication 135001 135016	prostate cancer
T1669	indication 135028 135042	stomach cancer
T1670	indication 135053 135073	head and neck cancer
T1671	tradename 135094 135102	TAXOTERE
T1672	tradename 135153 135162	TAXOTERE?
T1673	tradename 135179 135187	TAXOTERE
T1674	activeingredient 135251 135261	docetaxel,
T1675	tradename 135287 135296	TAXOTERE,
T1676	inactiveingredient 135336 135351	polysorbate 80.
T1677	tradename 135470 135479	TAXOTERE?
T1678	tradename 135632 135641	TAXOTERE?
T1679	tradename 135662 135671	TAXOTERE,
T1680	tradename 135768 135777	TAXOTERE?
T1681	tradename 135855 135864	TAXOTERE.
T1682	tradename 135994 136002	TAXOTERE
T1683	tradename 136102 136110	TAXOTERE
T1684	tradename 136196 136204	TAXOTERE
T1685	tradename 136361 136369	TAXOTERE
T1686	tradename 136607 136615	TAXOTERE
T1687	tradename 136758 136767	TAXOTERE?
T1688	tradename 136779 136787	TAXOTERE
T1689	routeofadministration 136815 136831	intravenous (IV)
T1690	tradename 136890 136898	TAXOTERE
T1691	frequency 136916 136930	every 3 weeks.
T1692	tradename 137007 137016	TAXOTERE.
T1693	tradename 137123 137131	TAXOTERE
T1694	tradename 137161 137170	TAXOTERE.
T1695	tradename 137342 137351	TAXOTERE.
T1696	tradename 137391 137410	TAXOTERE? TAXOTERE
T1697	tradename 137534 137543	TAXOTERE?
T1698	adversereaction 137556 137585	Acute Myeloid Leukemia (AML),
T1699	tradename 137640 137648	TAXOTERE
T1700	tradename 137822 137831	TAXOTERE.
T1701	adversereaction 137868 137910	redness and swelling of your arms and legs
T1702	adversereaction 137916 137937	peeling of your skin.
T1703	adversereaction 137979 138033	numbness, tingling, or burning in your hands and feet.
T1704	adversereaction 138071 138085	blurred vision
T1705	adversereaction 138089 138104	loss of vision.
T1706	tradename 138116 138124	TAXOTERE
T1707	tradename 138176 138184	TAXOTERE
T1708	tradename 138267 138275	TAXOTERE
T1709	tradename 138397 138405	TAXOTERE
T1710	tradename 138460 138468	TAXOTERE
T1711	adversereaction 138489 138519	changes in your sense of taste
T1712	adversereaction 138538 138553	short of breath
T1713	adversereaction 138564 138576	constipation
T1714	adversereaction 138587 138605	decreased appetite
T1715	adversereaction 138616 138655	changes in your fingernails or toenails
T1716	adversereaction 138666 138702	swelling of your hands, face or feet
T1717	adversereaction 138713 138734	feeling weak or tired
T1718	adversereaction 138745 138766	joint and muscle pain
T1719	adversereaction 138938 138944	nausea
T1720	adversereaction 138949 138957	vomiting
T1721	adversereaction 138968 138976	diarrhea
T1722	adversereaction 138987 139006	mouth or lips sores
T1723	adversereaction 139017 139026	hair loss
T1724	adversereaction 139037 139041	rash
T1725	adversereaction 139052 139086	redness of the eye, excess tearing
T1726	adversereaction 139097 139111	skin reactions
T1727	tradename 139127 139135	TAXOTERE
T1728	tradename 139278 139286	TAXOTERE
T1729	tradename 139458 139467	TAXOTERE.
T1730	tradename 139660 139668	TAXOTERE
T1731	tradename 139857 139866	TAXOTERE.
T1732	tradename 139987 139995	TAXOTERE
T1733	tradename 140111 140120	TAXOTERE?
T1734	activeingredient 140141 140150	docetaxel
T1735	inactiveingredient 140181 140188	ethanol
T1736	inactiveingredient 140193 140207	polysorbate 80
T1737	frequency 140209 140225	Every three-week
T1738	tradename 140239 140247	TAXOTERE
T1739	indication 140252 140318	breast, non-small cell lung and stomach, and head and neck cancers
T1740	routeofadministration 140329 140333	oral
T1741	co-administereddrug 140334 140348	corticosteroid
T1742	routeofadministration 140385 140389	Oral
T1743	co-administereddrug 140390 140404	corticosteroid
T1744	tradename 140496 140504	TAXOTERE
T1745	frequency 140562 140578	Every three-week
T1746	tradename 140592 140600	TAXOTERE
T1747	indication 140605 140620	prostate cancer
T1748	routeofadministration 140631 140635	oral
T1749	co-administereddrug 140636 140650	corticosteroid
T1750	routeofadministration 140772 140776	Oral
T1751	co-administereddrug 140777 140791	corticosteroid
T1752	tradename 140857 140865	TAXOTERE
T1753	company 140982 141005	sanofi-aventis U.S. LLC
T1754	company 141030 141044	SANOFI COMPANY
T1755	company 141070 141093	sanofi-aventis U.S. LLC
